Pfizer Inc.
Vectors for expression of prostate-associated antigens

Last updated:

Abstract:

The present disclosure provides (a) vectors comprising a multi-antigen construct encoding two, three, or more immunogenic PAA polypeptides; (b) compositions comprising the vectors, (c) methods relating to uses of the vectors and compositions for eliciting an immune response or for treating prostate cancers.

Status:
Grant
Type:

Utility

Filling date:

23 Aug 2018

Issue date:

16 Nov 2021